Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | University of California San Diego UCSD | 13 |
| 2 | University of California Berkeley | 9 |
| 3 | Sumitomo Pharma America Inc | 6 |
| 4 | University of California | 6 |
| 5 | AstraZeneca AB | 1 |
| 6 | Beijing Chaoyang Hospital | 1 |
| 7 | Janssen Pharmaceutica NV | 1 |
| 8 | University of Illinois System | 1 |
| 9 | Vanderbilt University | 1 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 38 |
| 2 | A61K | Medicinal preparations | 29 |
| 3 | C07C | Acyclic and carbocyclic compounds | 20 |
| 4 | C07D | Heterocyclic compounds | 19 |
| 5 | G01N | Investigating / analysing materials | 9 |
| 6 | C40B | 6 | |
| 7 | C12N | Microorganisms, enzymes | 4 |
| 8 | Y02A | Climate change adaptation | 1 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Cannabis and Cannabinoid Research | 4 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Daniele Piomelli | University of California, Irvine | 20 |
| 2 | Alexandros Makriyannis | University of Connecticut | 15 |
| 3 | Antonio Calignano | University of Naples Federico II | 8 |
| 4 | Cecilia J. Hillard | Medical College of Wisconsin | 7 |
| 5 | Fernando Rodrı́guez de Fonseca | Universidad Complutense de Madrid | 7 |
| 6 | Vincenzo Di Marzo | National Research Council | 7 |
| 7 | Francisco Silveira Guimarães | Universidade de São Paulo | 6 |
| 8 | Leonardo B.M. Resstel | Universidade de São Paulo | 6 |
| 9 | Massimiliano Beltramo | Neurosciences Institute | 6 |
| 10 | Boris B. Gorzalka | University of British Columbia | 5 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Modulation of anxiety through blockade of anandamide hydrolysis | 2002 | 1288 | Neurotransmitter Receptor Influence on Behavior |
| Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin‐like activity | 2000 | 349 | Neuroscience and Neuropharmacology Research |
| Anandamide Induces Apoptosis in Human Cells via Vanilloid Receptors | 2000 | 349 | Neuroscience and Neuropharmacology Research |
| Endogenous cannabinoid signaling is essential for stress adaptation | 2010 | 348 | Cannabis and Cannabinoid Research |
| Structural determinants for recognition and translocation by the anandamide transporter | 1999 | 270 | Neuroscience and Neuropharmacology Research |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of N-(4-hydroxyphenyl)icosa-5,8,11,14-tetraenamide?
Which institutions hold the most patents related to this compound?
What are the primary research topics associated with this compound?
Who are the most prolific researchers studying this compound?
What are the main patent classifications for this compound?